ProCE Banner Activity

Once-Weekly Oral ISL + LEN in Virologically Suppressed People Living With HIV: Wk 48 Results

Conference Coverage
Slideset

In final analysis of a open-label, active controlled phase II trial of weekly oral ISL plus LEN presented at HIV Glasgow 2024, high rates of virologic suppression were maintained at Week 48.

Released: November 14, 2024

Expiration: November 13, 2025

Share

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by educational grants from Gilead Sciences, Inc. and ViiV Healthcare.

Gilead Sciences, Inc.

ViiV Healthcare